Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Change in Receivables (2017 - 2025)

Dare Bioscience (DARE) has disclosed Change in Receivables for 8 consecutive years, with $181041.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables rose 139.5% year-over-year to $181041.0, compared with a TTM value of -$149729.0 through Sep 2025, up 75.49%, and an annual FY2024 reading of -$719229.0, up 4.6% over the prior year.
  • Change in Receivables was $181041.0 for Q3 2025 at Dare Bioscience, up from -$41866.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $9.4 million in Q2 2022 and bottomed at -$8.9 million in Q3 2022.
  • Average Change in Receivables over 5 years is -$5056.2, with a median of -$100099.5 recorded in 2021.
  • Peak annual rise in Change in Receivables hit 5846.62% in 2022, while the deepest fall reached 2813.02% in 2022.
  • Year by year, Change in Receivables stood at $989070.0 in 2021, then plummeted by 159.54% to -$588882.0 in 2022, then soared by 69.34% to -$180547.0 in 2023, then plummeted by 60.02% to -$288904.0 in 2024, then skyrocketed by 162.66% to $181041.0 in 2025.
  • Business Quant data shows Change in Receivables for DARE at $181041.0 in Q3 2025, -$41866.0 in Q2 2025, and -$288904.0 in Q4 2024.